相关实验视频

Updated: Jun 21, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

托西利祖马布诱导的牛皮发作:一个病例报告和一个基于病例的审查

Hubert Nielly¹, L Bialé², L Gilardin³

¹Service de Médecine interne, Hôpital d'Instruction des Armées Bégin, 69 avenue de Paris, Saint-Mandé, 94160, France. hubert.nielly@intradef.gouv.fr.

Rheumatology international

|July 16, 2024

概括

托西利祖马布 (TCZ) 可以诱导牛皮,这是一个罕见的副作用. 管理包括局部类固醇或药物停用,大多数患者在四周内得到改善.

科学领域:

类风湿病学类风湿病学
皮肤病学皮肤病学
药理学药理学是指药理学的学科.

背景情况:

在托西利祖马布 (TCZ) 治疗期间很少报告牛皮的发展.
这项研究详细介绍了TCZ相关的牛皮的新病例,并审查了现有的文献.

研究的目的:

描述在托西利祖马布治疗期间出现的一种新型牛皮病例.
对先前记录的托西利祖马布诱导的牛皮病例进行全面审查.

主要方法:

在主要数据库 (Medline/PubMed,Embase,Scopus,Web of Science,DOAJ) 进行了系统的文献搜索.
使用的关键词包括英语和法语中的"Tocilizumab"和"牛皮".
采用了基于案例的审查方法.

主要成果:

一名患有类风湿性关节炎的70岁女性在Infliximab后出现了牛皮发作,后者在Tocilizumab治疗后复发并在停止治疗后消失.
总共有16例托西利祖马布诱导的牛皮发作的病例被确定.
在有可用数据的14名患者中,有21%的患者先前患有牛皮,50%的患者先前使用过TNFα对抗剂.

结论:

对于托西利祖马布诱导的牛皮,最初的治疗可能包括局部类固醇,并在4周后重新评估.
如果没有效果,建议停止使用托西利祖马布并转换为治疗潜在疾病的替代药物.
在有限的场景中,可以考虑调整托西利祖马布的剂量或治疗方案,有效性至少在4周后进行评估.

关键词:

案例报告案例报告基于案例的审查.干细胞蛋白6 干细胞蛋白6 牛皮病是什么意思牛皮病副作用副作用副作用副作用托西利兹马布的使用方法

更多相关视频

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...